Sep 23,2014

LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing

LabStyle Innovations, developer of the Dario™ Diabetes Management Solution, today announced that it has closed a $4.2 million private placement offering consisting of shares of preferred stock and warrants. No placement agent was used for this financing. After estimated offering expenses, LabStyle expects to secure net proceeds of approximately $4.1 million from this financing. The lead investor in the offering is Dicilyon Consulting and Investment Ltd., an affiliate of Israeli investor David Edery, which has invested $3.0 million in the financing. The remaining investors were all institutional or accredited investors.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Carbon Health announces $100M in funding days after revealing layoffs

Carbon Health announced that the hybrid care provider had received $100 million in Series D investment from CVS Health Ventures days after revealing a second round of layoffs in the past year. The Series D funds will help Carbon Health scale its Connective Care model, which uses software to connect patients and healthcare providers, and allows for digital monitoring and management of care.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Jul 02,2019

AgaMatrix, Inc. and WaveForm Technologies, Inc. Complete $56 Million Capital Raise

AgaMatrix, Inc. (“AgaMatrix”) and WaveForm Technologies, Inc. (“WaveForm”), wholly owned subsidiaries of WaveForm Diabetes (formerly AgaMatrix Holdings, LLC), today announced that it closed on a total capital raise of $56 million. The raise includes over $6 million in financing from existing and new investors and $50 million in senior financing from Perceptive Advisors. The proceeds from the capital raise will be used for repayment of debt and to support increased production capacity, product development, and additional clinical trial initiatives for the commercialization of WaveForm’s Continuous Glucose Monitor (CGM) in Europe and FDA clearance in the USA.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 19,2022

Big Health Raises $75 Million in Series C Funding Led by SoftBank Vision Fund

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has raised $75 million in a Series C funding round, led by new investor SoftBank Vision Fund 2, with participation from ArrowMark Partners and existing investors Octopus Ventures, Gilde Healthcare, Kaiser Permanente Ventures (KPV), and Morningside Ventures.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jan 19,2022

NuvoAir Series A Funding Reaches $25M to Expand Patient-Centric Care and Clinical Trials Platform

NuvoAir, a leading digital healthcare company working in chronic disease management, raised $11M in a latest round of financing. The investment was led by Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures, and is an extension of the Series A round, previously announced in June 2021. Additional participation from a new strategic investor and existing investors brings the total Series A round to $25 million.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Feb 17,2022

MindMaze Secures $105 million in Funding

MindMaze (“the Company”), a global pioneer in the multi-billion dollar digital neurotherapy market, today announced that it has secured a financing of USD 105 million to accelerate its plans for global commercial growth, boost ongoing R&D and consolidate its development pipeline covering a broad spectrum of neurological diseases. The funding was led by Concord Health Partners, a US-based private equity firm, alongside other investors such as AlbaCore Capital Group.

FUNDING FUNDING ROUND

#r&d

View Analyst & Ambassador Comments
Go to original news
Feb 23,2022

Omada Health Closes $192 Million Series E Financing to Bring Virtual-First Care to Millions

Omada Health, a chronic care integrated healthcare provider, announced its $192 million Series E funding round led by Fidelity Management & Research Company with participation from aMoon, existing investors Perceptive Advisors, Wellington Management, Civilization Ventures, and others. The company also announced record growth and an expansion of its executive team and Board of Directors with the appointment of Taylor Harris as a new Board member, Nancy Vitale as Chief People Officer and Sunil Kayiti as Chief Technology Officer.

FUNDING SERIES E
View Analyst & Ambassador Comments
Go to original news
Mar 10,2022

HelloBetter scores €10 million in Series A round

Berlin-based, digital therapeutics firm HelloBetter has announced a €4 million extension of its €6 million Series A funding round, bringing the total investment round to €10 million. MassMutual Ventures (MMV) led, joined by existing investors HealthCap, Expon Capital and Sparrow Ventures. The funds will be used to push the commercialisation of HelloBetter’s products in the German market and advance its expansion beyond the DACH region. Hannes Klöpper, cofounder and CEO, HelloBetter, said: “We are excited to receive backing from yet another strong partner, as our category leadership in the field of digital therapeutics for mental health is becoming increasingly more visible.”

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

metaMe Health Raised $2.2 million Investment

Prescription digital therapeutic company metaMe Health raised $2.2 million in a bridge funding round led by Hyde Park Angels with participation from individual investors. The company will use the funding to prepare for the market launch of Regulora, a prescription digital therapeutic aimed at treating abdominal pain associated with irritable bowel syndrome in adults. The therapeutic received FDA 510(k) clearance late last year. metaMe said it plans to release Regulora in the second half of 2022.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

Woebot Health Secures $9.5 Million Investment From Leaps by Bayer

Woebot Health today announced that Leaps by Bayer, the impact investment arm of Bayer AG, has made a $9.5 million strategic investment in the company to help accelerate further development of its AI-powered behavioral health platform and products. The announcement follows Woebot Health’s $90 million Series B round in 2021 and brings total investment in the company to date to $123.5 million.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING